Technology

EPF’s patented technology is designed to address RF ablation’s greatest challenge: stability.

The novel catheter design includes:

  • Anchor
  • Circumferential Linear Array (CLA)
  • Catheter
  • Control Handle

Benefits

  • Stabilization – consistent CLA-to-tissue contact
  • Linear Electrodes – designed to create linear lesions
  • Single-shot – designed to simplify and reduce procedure time
  • Flow-thru design – no destabilizing backpressure

A PVI procedure with the EPF ‘Single-shot’ catheter starts the same as any PVI ablation procedure from femoral entry until after transseptal puncture and entry into the left atrium.

A guidewire is then inserted into a pulmonary vein (PV). The difference begins when the Anchor is deployed and expanded in the PV.

The CLA is deployed and compressed around the Ostium of the PV. Once both are stable the ablation can be initiated. Upon completion the procedure is repeated in each PV.

When all PVs are ablated the catheter is removed. The following describes the intended benefits of the innovative design as described by clinicians’ preferences:

  • Single-shot PV ablation is designed to simplify the procedure while reducing the occurrence of gaps.
  • Once the Anchor is deployed and expanded in the pulmonary vein (PV), it provides stability for the circumferential linear array (CLA).
  • Stable CLA contact during ablation is designed to deliver more precise and consistent energy into the tissue, resulting in more durable lesion formation.
  • Each adaptable circumferential electrode is designed to conform to variable tissue contour to create a continuous lesion.
  • Flow-thru design eliminates blood backpressure, minimizing CLA-to-tissue contact disruptions.
  • Designed for use with Radiofrequency energy, with provisions included for pulsed field ablation energy source.
Scroll